Hyperglycemia is linked to long-term organ dysfunction and damage. The purpose of this research is to examine a novel chemical made of thiadiazol derivatives for its possible anti-diabetic properties. Methods: Five groups were created from 60 adult male albino rats. Rats in Group I, the control group, received 1 ml of saline orally each day. Group II (positive control; intraperitoneally, streptozotocin at dose of 50 mg/kg was given. to animals in this group).Group III (control group) consists of diabetic rats given oral metformin at a dose of 100 mg/kg daily for 40 days. Group IV, V & VI rats orally administrated with chemical A, B & C for 40-day at dose of 50 mg/kg to diabetic rats. Blood serum and plasma samples, liver, kidney, and pancreatic tissues were obtained at the conclusion of the study period. The final body weight of diabetic rats significantly decreased, whereas the levels of plasma glucose, serum ALT, AST, ALB, TP, urea, creatinine, cholesterol, and triglycerides all increased. Compared to the control group, there was a significant decline in GST and CAT activities as well. Additionally, liver, kidney, and pancreas mean levels of IL-10 and HSP-70 highly increased as compared to the normal group. All elevated biochemical markers decreased after oral administration of newly synthesised thiadiazol derivatives chemicals, which also increased the activity of antioxidant enzymes. Reduce IL-10 and HSP-70 levels as well as compared to rats with diabetes. Studies on molecular docking demonstrated the presence of hydrogen bonds and hydrophobic interactions as well as energy-based confirmation of chemical binding to the proteins HSP- 70 and IL-10. Histopathological analysis of liver, kidney, and pancreatic tissues supported our findings. As a result of this investigation, it is possible that newly synthesised thiadiazol derivative chemicals have antioxidant and antihyperglycemic properties in streptozotocin-induced diabetic rats.